MedTrace Logo

Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

NCT07013591 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-02-18

No results posted yet for this study

Summary

The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.

Conditions

  • Coronary Artery Bypass Graft

Interventions

DRUG

MIB-626

An orally-administered stable crystalline tablet formulation of NMN

OTHER

Placebo

matching placebo tablets

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Shalender Bhasin, MB, BS · Brigham and Women's Hosptial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2028-10-01
Completion
2029-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07013591 on ClinicalTrials.gov